Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2014

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Revenue Recognized From Collaborations

The following table is a summary of the revenue recognized from the Company’s collaborations for each of the years ended December 31, 2014, 2013 and 2012.

	Year Ended December 31,
	2014		2013		2012
uniQure:
Milestone payment	$	14	$	531	$	198
Teva:
Recognition of upfront payment		12,255		13,143		927
Research funding		333		630		—
Genentech:
Recognition of upfront payment		3,603		3,300		3,431
Research funding		4,248		4,514		3,517
Milestone payment		7,913		5,062		—
Merck:
Recognition of initial payment		—		—		1,060
Option fee		—		—		2,060
Research funding		—		—		2,442
Genome BC:
Research funding		—		172		665
Total collaboration revenue	$	28,366	$	27,352	$	14,300